Loading...
XNAS
PPBT
Market cap226kUSD
Jul 09, Last price  
1.64USD
1D
3.80%
1Q
-60.29%
Jan 2017
-99.97%
Name

Purple Biotech Ltd

Chart & Performance

D1W1MN
XNAS:PPBT chart
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-47.02%
Rev. gr., 5y
115.44%
Revenues
0k
00000100,0001,000,0001,000,0001,000,00000195,80400
Net income
-26m
L+264.45%
-703-2,628,000-5,252,000-4,202,000-12,125,000-12,177,000-5,200,000-5,850,000-27,999,000-18,384,000-21,668,000-19,880-7,240,000-26,386,000
CFO
-6m
L-61.46%
-253-512,000-4,526,000-3,308,000-6,262,000-8,627,000-8,480,000-5,581,000-12,092,000-15,071,000-16,735,000-19,925,000-14,367,000-5,536,575

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Purple Biotech Ltd., a clinical-stage biotechnology firm based in Rehovot, Israel, is dedicated to pioneering treatments that help cancer patients, particularly in the United States, overcome tumor immune evasion and drug resistance. Its pipeline features two primary oncology assets: CM24: A monoclonal antibody designed to block carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). This candidate is undergoing Phase 1b/2 clinical trials, where it is being evaluated as a combination therapy with anti-PD-1 checkpoint inhibitors for non-small cell lung cancer and pancreatic cancer. NT219: A small molecule compound that targets insulin receptor substrate 1 and 2 (IRS1/2) as well as signal transducer and activator of transcription (STAT) pathways. NT219 is currently in Phase 1/2 clinical studies for the treatment of recurrent or metastatic solid tumors and squamous cell carcinoma of the head and neck. The company was formerly known as Kitov Pharma Ltd until its rebranding to Purple Biotech Ltd. in December 2020.
URL
https://purple-biotech.com/
IPO date
Sep 03, 1978
Employees
20
Domiciled in
IL
Incorporated in
IL

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT